Madam Speaker, the quick answer is no, I am not concerned, because I believe the opposite will happen. I sat on the industry committee when we looked at the patent laws of our country compared to other countries we import products from, and at the intellectual property debates we have had in the country. Frankly, we have a big reform to do to make sure our pharmaceutical costs stay competitive with other jurisdictions', as sometimes they are not because of the rules and regulations.
The more we harmonize with developed economies, such as the 28 European countries who are part of this deal, and the United States, our neighbour, and the more we bring those harmonization rules to patenting and intellectual property, the more consumers will benefit at the end of the day. It is a process. It is a transition, but I totally disagree with the premise of that question.